Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 1,699
Change Today +5.00 / 0.30%
Volume 139.8K
KMDA On Other Exchanges
Tel Aviv
As of 10:24 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

kamada ltd (KMDA) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/12/14 - $4,953
52 Week Low
11/25/14 - $1,160
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KAMADA LTD (KMDA)

kamada ltd (KMDA) Related Businessweek News

No Related Businessweek News Found

kamada ltd (KMDA) Details

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company’s lung disease products include Glassia used in augmentation and maintenance therapy in adults with emphysema due to congenital intravenous AAT deficiency (AATD); Bramitob to manage chronic pulmonary infection; and FOSTER for regular treatment of asthma. Its immunoglobulin products comprise KamRAB for prophylaxis against rabies infection; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for the treatment of various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. The company also provides critical care products, such as Heparin Lock Flush to maintain patency of indwelling IV catheter; Heparin sodium injection to treat thrombo-embolic disorders; Kamacaine 0.5% used as anesthesia or analgesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; and Albumin for maintenance of circulating blood volume. In addition, it offers Transferrin for diagnostic assays and cell cultures; and coagulation factors, including Factor VIII, Factor IX, and Human Transferrin. Further, the company develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, chronic obstructive pulmonary diseases, graft-versus-host diseases, and transplantations. It has collaboration partnerships with PARI and Baxter Healthcare Corporation. The company markets its products through strategic partners in the United States; and distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

Founded in 1990

kamada ltd (KMDA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $1.5M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $347.0K
Vice President of Operations and Plant Manage...
Total Annual Compensation: $232.0K
Vice President of Clinical Development & IP
Total Annual Compensation: $177.0K
Vice President of Research and Development
Total Annual Compensation: $199.0K
Compensation as of Fiscal Year 2013.

kamada ltd (KMDA) Key Developments

Kamada Ltd. Announces Management Changes, Effective from July 2015

Kamada Ltd. announced executive management changes intended to strengthen the company’s leadership while benefiting from its accomplished executives and advancing its protein therapeutics platform. Under the changes, David Tsur, co-founder and Chief Executive Officer, will become Deputy Executive Chairman of the Board, a new position whereby he will maintain his strategic advisory role yet relinquish day-to-day management responsibilities. Leon Recanti will remain the Chairman of the Board. Amir London, the company’s Senior Vice President of Business Development, will become Chief Executive Officer and Gil Efron, currently Chief Financial Officer, will take on the added role of Deputy Chief Executive Officer. The changes are expected to go into effect in July 2015.

Kamada Ltd. Reports Additional Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat

Kamada Ltd. announced additional results from its European Phase 2/3 clinical trial of the company’s inhaled alpha-1 antitrypsin (AAT) to treat AAT deficiency (AATD). Kamada performed these post hoc analyses in accordance with guidance received following the company’s meeting with European Medicines Agency (EMA) Rapporteurs in December 2014. The goal of these analyses is to further evaluate lung function results using the most rigorous statistical methods to confirm that the efficacy signal previously identified is valid and robust. Lung Function Results: Results from the post hoc analyses indicate that after one year of daily inhalation of Kamada’s AAT, clinically and statistically significant improvements were seen in spirometric measures of lung function, particularly in bronchial airflow measurements FEV1 (L), FEV1% predicted and FEV1/SVC. These favorable results were even more evident when analyzing the overall treatment effect throughout the full year. For lung function, overall one year effect: FEV1 (L) rose significantly in AAT treated patients and decreased in placebo treated patients (+15ml for AATvs. -27ml for placebo, a 42 ml difference, p=0.0268). There was a trend towards better FEV1% predicted (0.54% for AAT vs. -0.62% for placebo, a 1.16% difference, p=0.065). FEV1/SVC% rose significantly in AAT treated patients and decreased in placebo treated patients (0.62% for AATvs. -0.87% for placebo, a 1.49% difference, p=0.0074). For lung function change at week 50 vs. baseline: There was a trend towards reduced FEV1 (L) decline (-12ml for AAT vs. -62ml for placebo, a 50 ml difference, p=0.0956). There was a trend towards a reduced decline in FEV1% predicted (-0.1323% for AAT vs. -1.6205% for placebo, a 1.4882% difference, p=0.1032). FEV1/SVC% rose significantly in AAT treated patients and decreased in placebo treated patients (0.61% for AAT vs. -1.07% for placebo, a 1.68% difference, p=0.013).

Kamada Ltd. Gets European Orphan Drug Designation for its Alpha-1 Antitrypsin to Treat Graft-Versus-Host Disease

Kamada Ltd. announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA), has designated the company’s proprietary human intrevenous (IV) Alpha-1 Antitrypsin (AAT) as an orphan medicinal product to treat Graft-versus-host disease (GvHD). In October 2014 Kamada received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for its AAT by IV to treat GvHD. Preliminary human and animal studies indicate that AAT may be able to treat and reduce the severity of GvHD, which is one of the key, life-threatening complications of allogeneic stem cell transplantation. GvHD is an immunologically-based disease that may result in significant damage to multiple organs and tissues such as the liver, gastrointestinal tract, skin and mucosal membranes. Tissue destruction also leads to increased inflammatory signals, perpetuating and augmenting the disease process by contributing to the cytokine storm that fuels GvHD even further and, thereby, the damage continues and its intensity is increased. In recent years, AAT has been investigated extensively and found to have anti-inflammatory, tissue-protective, immune-modulatory and anti-apoptotic properties in direct or indirect consequence of its underlying anti-protease capabilities. These properties may attenuate inflammation by lowering levels of pro-inflammatory mediators such as cytokines, chemokines and proteases that are associated with this severe disease. Kamada’s AAT therapy is being investigated in a clinical U.S. Phase 1/2 study that is evaluating 24 GvHD patients with inadequate response to steroid treatment following allogeneic bone-marrow stem cell transplant. The patients are enrolled into 4 dose cohorts, in which they receive up to 8 doses of Kamada’s AAT. The study is being conducted by the Fred Hutchinson Cancer Research Center in Seattle in cooperation with Baxter International. Interim results from this study were presented in a poster at the American Society of Hematology Annual Meeting in December 2014. Preliminary results indicated that continuous administration of AAT as therapy for steroid-resistant gut GvHD is feasible in the subject population. Indication of healing of the bowel mucosa was seen in a decrease in diarrhea, in a decrease in intestinal AAT loss, and improvement in endoscopic evaluation. Additionally, in the preliminary results AAT administration suppressed serum levels of pro-inflammatory cytokines and interfered with GvHD biomarkers.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KMDA:IT 1,699.00 +5.00

KMDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €36.98 EUR -1.16
View Industry Companies

Industry Analysis


Industry Average

Valuation KMDA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAMADA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at